Singapore markets closed

Ikena Oncology, Inc. (IKNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3000-0.0100 (-0.76%)
At close: 04:00PM EDT
1.2800 -0.02 (-1.54%)
After hours: 06:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3100
Open1.3000
Bid1.2800 x 100
Ask1.3100 x 200
Day's range1.2800 - 1.3364
52-week range1.0200 - 7.6400
Volume120,388
Avg. volume411,874
Market cap62.736M
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-1.6300
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.33
  • GlobeNewswire

    Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

    BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. Details are as follows: Date: Tuesday, April 16, 2024Time: 2:00 p.m. ETWebcast

  • Simply Wall St.

    Ikena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

    Ikena Oncology ( NASDAQ:IKNA ) Full Year 2023 Results Key Financial Results Net loss: US$68.2m (flat on FY 2022...

  • GlobeNewswire

    Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

    IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”)